458 related articles for article (PubMed ID: 23979365)
1. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
[TBL] [Abstract][Full Text] [Related]
2. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy.
Levi M; Vincent JL; Tanaka K; Radford AH; Kayanoki T; Fineberg DA; Hoppensteadt D; Fareed J
Crit Care Med; 2020 Aug; 48(8):1140-1147. PubMed ID: 32697484
[TBL] [Abstract][Full Text] [Related]
3. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.
Saito H; Maruyama I; Shimazaki S; Yamamoto Y; Aikawa N; Ohno R; Hirayama A; Matsuda T; Asakura H; Nakashima M; Aoki N
J Thromb Haemost; 2007 Jan; 5(1):31-41. PubMed ID: 17059423
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.
Hoppensteadt D; Tsuruta K; Cunanan J; Hirman J; Kaul I; Osawa Y; Fareed J
Clin Appl Thromb Hemost; 2014 Mar; 20(2):129-35. PubMed ID: 23804232
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
[TBL] [Abstract][Full Text] [Related]
8. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
Vincent JL; Francois B; Zabolotskikh I; Daga MK; Lascarrou JB; Kirov MY; Pettilä V; Wittebole X; Meziani F; Mercier E; Lobo SM; Barie PS; Crowther M; Esmon CT; Fareed J; Gando S; Gorelick KJ; Levi M; Mira JP; Opal SM; Parrillo J; Russell JA; Saito H; Tsuruta K; Sakai T; Fineberg D;
JAMA; 2019 May; 321(20):1993-2002. PubMed ID: 31104069
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
[TBL] [Abstract][Full Text] [Related]
10. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
[TBL] [Abstract][Full Text] [Related]
13. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
Mitaka C; Kawagoe I; Satoh D; Hayashida M
Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
[TBL] [Abstract][Full Text] [Related]
14. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.
Ito T; Thachil J; Asakura H; Levy JH; Iba T
Crit Care; 2019 Aug; 23(1):280. PubMed ID: 31416465
[TBL] [Abstract][Full Text] [Related]
15. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis.
Lin SM; Wang YM; Lin HC; Lee KY; Huang CD; Liu CY; Wang CH; Kuo HP
Crit Care Med; 2008 Mar; 36(3):683-9. PubMed ID: 18431261
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
[TBL] [Abstract][Full Text] [Related]
19. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
[TBL] [Abstract][Full Text] [Related]
20. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
